Research programme: autoimmune disease monoclonal antibodies - ChemomAb

Drug Profile

Research programme: autoimmune disease monoclonal antibodies - ChemomAb

Alternative Names: CM-101 - ChemomAb; CM-102; CM-301

Latest Information Update: 18 Dec 2013

Price : $50

At a glance

  • Originator ChemomAb
  • Class Monoclonal antibodies
  • Mechanism of Action CCR3 receptor antagonists; Chemokine CCL 5 inhibitors; Chemokine CCL11 inhibitors; Chemokine CCL24 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; Inflammation; Rheumatoid arthritis

Most Recent Events

  • 18 Dec 2013 Preclinical trials in Rheumatoid arthritis in Israel (Parenteral)
  • 18 Dec 2013 Preclinical trials in Autoimmune disorders in Israel (Parenteral)
  • 18 Dec 2013 Preclinical trials in Inflammation in Israel (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top